These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 25166271)
21. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization. Parravano M; Ricci F; Oddone F; Missiroli F; De Felici C; Varano M Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101 [TBL] [Abstract][Full Text] [Related]
22. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846 [TBL] [Abstract][Full Text] [Related]
23. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Oishi A; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Nakata I; Miyake M; Yoshimura N Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):1-7. PubMed ID: 22527326 [TBL] [Abstract][Full Text] [Related]
24. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991 [TBL] [Abstract][Full Text] [Related]
25. Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy? Milani P; Pellegrini M; Massacesi A; Moschini S; Setaccioli M; Soranna D; Zambon A; Bottoni F; Bergamini F Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1713-1720. PubMed ID: 28667483 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547 [TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related]
33. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity. Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939 [TBL] [Abstract][Full Text] [Related]
37. Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Uemoto R; Nakasato-Sonn H; Kawagoe T; Akira M; Okada E; Mizuki N Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):989-97. PubMed ID: 22270217 [TBL] [Abstract][Full Text] [Related]
38. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Iacono P; Battaglia Parodi M; Iuliano L; Bandello F Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725 [TBL] [Abstract][Full Text] [Related]